Erschienen in:
Open Access
01.12.2022 | Correction
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
verfasst von:
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, Florindo d’Onofrio, Maria Albanese, Ilaria Cetta, Paola Di Fiore, Maurizio Zucco, Massimo Filippi, Francesco Bono, Claudia Altamura, Stefania Proietti, Stefano Bonassi, Fabrizio Vernieri, and for the FRIEND-Study Group
Erschienen in:
The Journal of Headache and Pain
|
Ausgabe 1/2022
Correction to: J Headache Pain 22, 46 (2022)
https://doi.org/10.1186/s10194-022-01396-x
Following the publication of the original article [
1], we were notified that the name of the 9
th author was incorrectly spelled as Massimo FilippiBonassi, instead of Massimo Filippi.
The original article has been corrected.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.